Ultragenyx Pharma (RARE) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ultragenyx Reports Second Quarter 2017 Financial Results and Corporate Update
July 27, 2017 4:06 PM EDTNOVATO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended June 30, 2017.
We look forward to submitting our biologics license application (BLA) for burosumab and working with the FDA to bring this potential treatment to adult and pediatric patients, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. We believe the first bone biopsy data from our ongoing Phase 3... More
